Alebund's AP301 NDA Accepted for Review by China's NMPA

NDA FilingAP301Positive

AI Analysis

Summary

Alebund Pharmaceuticals announced that its New Drug Application for AP301 capsules, an oral iron-based phosphate binder, has been accepted for review by China's NMPA. This represents a regulatory milestone for the renal-focused biopharmaceutical company.

Outcome Details

NDA accepted for review by China's NMPA

Importance:6/10

Sentiment:

0.60

regulatoryChinaNMPANDAnephrologyiron-based phosphate binder

Related Companies

$09637

Read the original article

Published by PR Newswire Biotech on August 7, 2026 10:34 AM

Read Original